CovidImmunEye: Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre

Sponsor
University Hospital Tuebingen (Other)
Overall Status
Unknown status
CT.gov ID
NCT04446338
Collaborator
Institute of Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine (Other)
300
1
2.6
114.1

Study Details

Study Description

Brief Summary

A sequential combination of different antibodies test against SARS-CoV-2 is evaluated. The protocol included a rapid test and several ELISA tests within a defined cohort of healthcare workers.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Antibody Test

Detailed Description

In the current pandemic, the assessment of actual COVID-19 infections plays an important role in the assessment of the risk and progress of the epidemic. Shortly, more and more rapid tests will be available, the aim of which is to be able to obtain a good overview of the immune status of corresponding samples in a timely manner.

Employees in the health sector are faced with additional challenges, not only due to the tightened hygiene regulations. The concern about infecting other people and/or exposing oneself to a relevant health risk is of great importance. A moderate to high transmission risk can be assumed for ophthalmology. In view of older patients and sometimes unavoidable proximity, targeted and reliable diagnostics can offer the potential to reduce the risk potential for the current situation by determining antibodies.

A rapid diagnosis is not yet available outside of clinical studies, especially since deficits in specificity (contact with other coronaviruses) are to be expected. Studies on the serological reaction are not yet available for longer observation periods, but it can be assumed that positive direct detection of IgG (Anti Sars-CV-2-ELISA; Euroimmun) is available at the latest 3 weeks after the onset of symptoms. Without larger and representative analyses, it is currently unclear whether seroconversion is associated with permanent immunity or a lack of it leads to a possible susceptibility to reinfection. A combined test procedure is therefore to be offered to employees within the framework of a random sample.

The query of anamnestic parameters allows the assignment to different groups (CC: past COVID infection, PC: possible infection, N: asymptomatic). The primary goal of the planned study is to provide a first preliminary evaluation of the tests used in the current context.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Immune Status: Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Sample of the Eye Department (University Eye Hospital and Research Institute Tübingen)
Actual Study Start Date :
May 13, 2020
Anticipated Primary Completion Date :
Jun 30, 2020
Anticipated Study Completion Date :
Aug 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Healthcare Worker

Staff of the Department of Ophthalmology, University Tuebingen, Germany

Diagnostic Test: Antibody Test
Presence and Titer of Anti-Sars-CoV-2 Antbodies

Outcome Measures

Primary Outcome Measures

  1. Seroprevalence [through study completion, maximum of one year]

    Rate of anti-SARS-CoV-2 Antibodies

Secondary Outcome Measures

  1. Agreement of the test results and questionnaire [through study completion, maximum of one year]

    Kappa statistics

  2. Positive predictive / negative values of the tests applied [through study completion, maximum of one year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Employees of the health facility described

  • voluntary request for testing

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Tuebingen Tuebingen BW Germany 72076

Sponsors and Collaborators

  • University Hospital Tuebingen
  • Institute of Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital Tuebingen
ClinicalTrials.gov Identifier:
NCT04446338
Other Study ID Numbers:
  • 292/2020BO2
First Posted:
Jun 24, 2020
Last Update Posted:
Jun 24, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital Tuebingen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 24, 2020